These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36834803)

  • 1. PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab')
    Xu M; Bi J; Liang B; Wang X; Mo R; Feng N; Yan F; Wang T; Yang S; Zhao Y; Xia X
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Equine immunoglobulin fragment F(ab')
    Gupta D; Ahmed F; Tandel D; Parthasarathy H; Vedagiri D; Sah V; Krishna Mohan B; Khan RA; Kondiparthi C; Savari P; Jain S; Reddy S; Kumar JM; Khan N; Harshan KH
    Clin Immunol; 2022 Apr; 237():108981. PubMed ID: 35306171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection.
    Li E; Han Q; Bi J; Wei S; Wang S; Zhang Y; Liu J; Feng N; Wang T; Wu J; Yang S; Zhao Y; Liu B; Yan F; Xia X
    Front Immunol; 2023; 14():1066730. PubMed ID: 36875106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulating pharmacokinetics of an anti-interleukin-8 F(ab')(2) by amine-specific PEGylation with preserved bioactivity.
    Koumenis IL; Shahrokh Z; Leong S; Hsei V; Deforge L; Zapata G
    Int J Pharm; 2000 Mar; 198(1):83-95. PubMed ID: 10722953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.
    Xu Y; Jia Z; Zhou L; Wang L; Li J; Liang Y; Zhao T; Ni B; Wu Y
    Int Immunopharmacol; 2007 Dec; 7(13):1834-40. PubMed ID: 17996696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2.
    Barbier M; Lee KS; Vikharankar MS; Rajpathak SN; Kadam N; Wong TY; Russ BP; Cyphert HA; Miller OA; Rader NA; Cooper M; Kang J; Sen-Kilic E; Wong ZY; Winters MT; Bevere JR; Martinez I; Devarumath R; Shaligram US; Damron FH
    Front Immunol; 2022; 13():948431. PubMed ID: 36091051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and development of equine hyperimmune globulin F(ab')2 against severe acute respiratory syndrome coronavirus.
    Lu JH; Guo ZM; Han WY; Wang GL; Zhang DM; Wang YF; Sun SY; Yang QH; Zheng HY; Wong BL; Zhong NS
    Acta Pharmacol Sin; 2005 Dec; 26(12):1479-84. PubMed ID: 16297347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
    Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
    Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of mammalian cells from severe acute respiratory syndrome coronavirus infection by equine neutralizing antibody.
    Wang X; Ni B; Du X; Zhao G; Gao W; Shi X; Zhang S; Zhang L; Wang D; Luo D; Xing L; Jiang H; Li W; Jiang M; Mao L; He Y; Xiao Y; Wu Y
    Antivir Ther; 2005; 10(5):681-90. PubMed ID: 16152762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyclonal F(ab')
    Cunha LER; Stolet AA; Strauch MA; Pereira VAR; Dumard CH; Gomes AMO; Monteiro FL; Higa LM; Souza PNC; Fonseca JG; Pontes FE; Meirelles LGR; Albuquerque JWM; Sacramento CQ; Fintelman-Rodrigues N; Lima TM; Alvim RGF; Marsili FF; Caldeira MM; Zingali RB; de Oliveira GAP; Souza TML; Silva AS; Muller R; Rodrigues DDRF; Jesus da Costa L; Alves ADR; Pinto MA; Oliveira AC; Guedes HLM; Tanuri A; Castilho LR; Silva JL
    iScience; 2021 Nov; 24(11):103315. PubMed ID: 34723156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
    Glennie MJ; McBride HM; Worth AT; Stevenson GT
    J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab].
    Sedlacek HH; Gronski P; Hofstaetter T; Kanzy EJ; Schorlemmer HU; Seiler FR
    Klin Wochenschr; 1983 Aug; 61(15):723-36. PubMed ID: 6194337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of an antigen-binding capture ELISA for native and putrescine-modified anti-tetanus F(ab')2 fragments for the assessment of the cellular uptake and plasma kinetics of the antibodies.
    Welfringer F; d'Athis P; Scherrmann JM; Hervé F
    J Immunol Methods; 2005 Dec; 307(1-2):82-95. PubMed ID: 16305797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 equine F (Ab')
    Botosso VF; Jorge SAC; Astray RM; de Sá Guimarães AM; Mathor MB; de Carneiro PDS; Durigon EL; Covas D; de Oliveira DBL; das Neves Oliveira R; Maria DA; Eto SF; Gallina NMF; Pidde G; Squaiella-Baptistão CC; Silva DT; Villas-Boas IM; Fernandes DC; Auada AVV; Banari AC; de Souza Filho AF; Bianconi C; de Agostini Utescher CL; Oliveira DCA; Mariano DOC; Barbosa FF; Rondon G; Kapronezai J; da Silva JG; Goldfeder MB; Comone P; Junior REC; Pereira TTS; Wen FH; Tambourgi DV; Chudzinski-Tavassi AM
    Sci Rep; 2022 Mar; 12(1):3890. PubMed ID: 35273234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
    Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
    Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New method to produce equine antirabies immunoglobulin F(ab')₂ fragments from crude plasma in high quality and yield.
    Kittipongwarakarn S; Hawe A; Tantipolphan R; Limsuwun K; Khomvilai S; Puttipipatkhachorn S; Jiskoot W
    Eur J Pharm Biopharm; 2011 Jun; 78(2):189-95. PubMed ID: 21414404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
    Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
    Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom.
    Pepin-Covatta S; Lutsch C; Lang J; Scherrmann JM
    J Pharm Sci; 1998 Feb; 87(2):221-5. PubMed ID: 9519157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.